SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA
THE SECOND CONGRESS OF THE SERBIAN ASSOCIATION FOR CANCER RESEARCH WITH INTERNATIONAL PARTICIPATION „CANCER RESEARCH: PERSPECTIVES AND APPLICATION“
Belgrade, Serbia, 2-3 October, 2015
Friday, 2nd October 2015
08.00 – 09.00 Registration
09.00 – 09.30 Opening Ceremony
Welcome speech by dr Zorica Juranić, president of SDIR
Welcome speech by dr Siniša Radulović, co-president of SDIR2 congress
Welcome speech by prof. dr Radan Džodić, director of the Institute of Oncology and Radiology of Serbia, president of Oncology Section of the SLD
09.30 – 11.15 Plenary lectures
Chairmen: Zorica Juranić, Siniša Radulović, Radan Džodić
09.30 – 10.00 *Lecture sponsored by EACR
1. *Keisari Y1, Confino H.1, Schmidt M.2, Umansky V.3 Kelson I1,2.
1Sackler Faculty of Exact Sciences, Tel Aviv University, Israel, 2, German Cancer Research Center, Heidelberg, 3Ruprecht-Karl University of Heidelberg, Mannheim, Germany. Cure of metastatic tumors by intratumoral alpha radiation in combination with immunostimulants and inhibitors of immune suppressor cells.
10.00 – 10.30
2. Novaković S.
Institute of Oncology, Ljubljana, Slovenia
Tumor vaccines and their role in oncology: Our experience with the creation of different tumor vaccines
10.30 – 11.00
3. Solary E. *Lecture sponsored by EACR
Gustave Roussy, Paris, France
Chronic myelomonocytic leukemia, pathophysiological insights
11.00 – 11.15 Discussion
11.15 – 11.45 Coffee break
11.45 – 13.30 Session: Immune response and its modulation in cancer
Chairmen: Zorica Juranic, Gordana Konjevic, Yona Keisari
11.45 – 12.00
1. Popović L.
Oncology Institute of Vojvodina, Sremska Kamenica, Medical School Novi Sad, University of Novi Sad, Novi Sad Serbia
Anti-PD1/PDL1 checkpont inhibitors: a new frontier in cancer immunotherapy
12.00 – 12.15
2. Cikota Aleksić B.
Institute of Medical Research, MMA, Belgrade, Serbia
The association of TNF-alpha, FCGR2A, FCGR3a and FN genes polymorphism with characteristics, course and outcome of diffuse large B-cell lymphoma.
12.15 – 12.30
3. Besu-Žižak I.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
The role of immunoreactivity to food proteins in the etiopathogenesis of different diseases
12.30 – 12.45
4. Mirjačić Martinović K.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Functional and immunophenotypic characteristics of NK cells and their subsets in metastatic melanoma patients
12.45 – 13.00
5. Vuletić A.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
In vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15
13.00 – 13.15
6. Matić I.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
CD26 in various malignancies
13.15 – 13.30 Discussion
13.30 – 15.00 Lunch
15.00 – 16.30 Session: Molecular changes in cancer development and progression I
Chairmen: Mirjana Branković Magić/Srđan Novaković
15.00 – 15.15
1. Tanić M.
UCL Cancer Institute, University College London, London, UK
Tracking (epi)genomic landscape during cancer progression in circulating tumor DNA
15.15 – 15.30
2. Krivokuća A.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Hereditary breast cancer genetics: looking for BRCA3?
15.30 – 15.45
3. Šupić G.
MMA Medical School, Institute of Medical Research, MMA, Belgrade, Serbia
Cancer epigenetics: from mechanisms to clinical applications
15.45 – 16.00
4. Gužvić M.
Faculty of Medicine, University of Regensburg (Germany)
Identification and molecular characterization of metastasis founder cells
16.00 – 16.15
5. Ozretić P.
Ruđer Bošković Institute, Zagreb, Croatia,
Expression of PTCH1b Tumor Suppressor Gene Is Controlled by Different 5′ Untranslated Region Cis-Regulatory Elements
16.15 – 16.30 Discussion
16.30 – 17.00 Coffee break
17.00 – 18.30 Session: Clinical oncology: Era of molecular markers
Chairmen: Džodić Radan/Radmila Janković
17.00 – 17.15
1. Džodić R.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Lymphonodal metastases in clinically N0 patients with incidental thyroid microcarcinomas.
17.15 – 17.30
2. Zarić B.
Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Vojvodina
Academic clinical trials in diagnostics and therapy of lung cancer in Serbia – era of advanced technology and molecular biology
17.30 – 17.45
3. Jezeršek Novaković B.
Institute of Oncology , Ljubljana, Slovenia
The diffuse large B cell lymphoma – can we at least approach study results in everyday clinical practice
17.45 – 18.00
4. Tomašević Z.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Breast cancer and brain metastases: clinical, pathological and molecular characteristics
18.00 – 18.15
5. Radosavljević D.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Metastatic lung and colorectal cancer: Impact of molecular markers on systemic treatment – Serbian experience
18.15 – 18.30 Discussion
Saturday, 3rd October 2015.
09.00 – 10.00 Plenary lectures
Chairmen: Zorica Juranić, Siniša Radulović
09.00 – 09.30 *Lecture sponsored by EACR
1. Ulukaya E.
Medical School of Uludag University, Bursa, Turkey
Palladium (II)-based anticancer compounds: A new hope or an illusion?
09.30 – 10.00
2. Dimas K.
School of Health Sciences, University of Thessaly, Larissa, Greece
Sigma receptors as targets for the development of novel targeted anticancer therapies
10.00 – 10.15 Discussion
10.15 – 11.15 Session: Anticancer drugs investigation I
Chairmen: Siniša Radulovic/Engin Ulukaya
10.15 – 10.30
1. Pešić M.
Institute for Biological Research, „Sinisa Stankovic”, Belgrade, Serbia
New approaches in overcoming multidrug resistance in cancer
10.30 – 10.45
2. Bogdanović G
Academy of Medical Sciences of the Serbian Medical Society, Belgrade
Fullerenes: biological activity and potential biomedical application
10.45 – 11.00
3. Aranđelović S.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Platinum complexes as anticancer-drugs: properties and perspectives
11.00 – 11.15 Discussion
11.15 – 12.00 Coffee break
12.00 – 13.00 Session: Anticancer drug investigation II
Chairmen: Konstantinos Dimas/Gordana Bogdanović
12.00 – 12.15
1. Gligorijevic N.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Development of Ru(II)-arene complexes with pyridine derivatives as anticancer agents
12.15-12.30
2. Žižak T.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Antitumor activities of macrofungi extracts
12.30 – 12.45
3. Čavić M.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
G protein-coupled receptor heteromers as new pharmacological targets in lung cancer
12.45 – 13.00 Discussion
13.00 – 14.00 Session: Molecular changes in cancer development and progression II
Chairmen: Karmen Stankov/Sonja Levanat
13.00 – 13.15
1. Slade N.
Ruđer Boškovic Insitute, Zagreb, Croatia
p53/p63/p73 protein network
13.15 – 13.30
2. Radulović M.
Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
Image Analysis of Breast Tumour Histology Images in Prognosis of Distant Metastasis Risk
13.30–-13.45
3. Stankov K.
Clinical Center of Vojvodina, Medical School Novi Sad, University of Novi Sad, Novi Sad, Serbia
C-KIT signaling in cancer
13.45 – 14.00 Discussion
14.00 – 15.30 Lunch
15.30 – 17.00 Poster Session & Short talks
17.00 – 17.30 Coffee break
17.30 – 18.30
Best Poster Award
Closing remarks